Role of C-reactive protein in atherogenesis;Znaczenie białka C-reaktywnego w patofizjologii Miazdzycy

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 60, Issue , 2006, Pages 538-546

  Boncler, Magdalena ^a   Luzak, Bogusława ^a   Watała, Cezary ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Atherogenesis; C reactive protein; Cardiovascular disease

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN;

BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; HEART INFARCTION; HUMAN; IMMUNOASSAY; IMMUNOLOGY; INFLAMMATION; METABOLISM; REVIEW; RISK ASSESSMENT;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERIOSCLEROSIS; HUMANS; IMMUNOASSAY; INFLAMMATION; MYOCARDIAL INFARCTION; RISK ASSESSMENT;

EID: 39049187632     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Agrawal A., Xu Y., Ansardi D., Macon K.J., Volanakis J.E.: Probing the phosphocholine-binding site of human C-reactive protein by sitedirected mutagenesis. J. Biol. Chem., 1992; 267: 25353-25358
2. Ahmed N., Thorley R., Xia D., Samols D., Webster R.O.: Transgenic mice expressing rabbit C-reactive protein exhibit diminished chemotactic factor-induced alveolitis. Am. J. Respir. Crit Care Med., 1996; 153: 1141-1147
3. Bang R., Marnell L., Mold C., Stein M.P., Clos K.T., Chivington-Buck C., Clos T.W.: Analysis of binding sites in human C-reactive protein for FcgRI, FcgRIIA, and C1q by site-directed mutagenesis. J. Biol. Chem., 2005; 280: 25095-25102
4. Berger P., McConnell J.P., Nunn M., Kornman K.S., Sorrell J., Stephenson K., Duff G.W.: C-reactive protein levels are influenced by common IL-1 gene variations. Cytokine, 2002; 17: 171-174
5. Bhakdi S., Torzewski M., Klouche M., Hemmes M.: Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler. Thromb. Vasc. Biol., 1999; 19: 2348-2354
6. Bharadwaj D., Stein M.P., Volzer M., Mold C., Du Clos T.W.: The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J. Exp. Med., 1999; 190: 585-590
7. Boudjeltia Z.K., Piagnerelli M., Brohee D., Guillaume M., Cauchie P., Vincent J.L., Remacle C., Bouckaert Y., Vanhaeverbeek M.: Relationship between CRP and hypofibrinolysis: Is this a possible mechanism to explain the association between CRP and outcome in critically ill patients? Thromb. J., 2004; 2: 7
8. Brull D.J., Serrano N., Zito F., Jones L., Montgomery H.E., Rumley A., Sharma P., Lowe G.D., World M.J., Humphries S.E., Hingorani A.D.: Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler. Thromb. Vasc. Biol., 2003; 23: 2063-2069
9. Buchta R., Fridkin M., Pontet M., Contessi E., Scaggiante B., Romeo D.: Modulation of human neutrophil function by C-reactive protein. Eur. J. Biochem., 1987; 163: 141-146
10. Calabro P., Willerson J.T., Yeh E.T.: Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation, 2003; 108: 1930-1932
11. Carlson C.S., Aldred S.F., Lee P.K., Tracy R.P., Schwartz S.M., Rieder M., Liu K., Williams O.D., Iribarren C., Lewis E.C., Fornage M., Boerwinkle E., Gross M., Jaquish C., Nickerson D.A., Myers R.M., Siscovick D.S., Reiner A.P.: Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am. J. Hum. Genet., 2005; 77: 64-77
12. Cermak J., Key N.S., Bach R.R., Balla J., Jacob H.S., Vercellotti G.M.: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood, 1993; 82: 513-520
13. Chang M.K., Binder C.J., Torzewski M., Witztum J.L.: C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc. Natl. Acad. Sci. USA, 2002; 99: 13043-13048
14. Chi M., Tridandapani S., Zhong W., Coggeshall K.M., Mortensen R.F.: C-reactive protein induces signaling through Fc gamma RIIa on HL-60 granulocytes. J. Immunol., 2002; 168: 1413-1418
15. Ciubotaru I., Potempa L.A., Wander R.C.: Production of modified C-reactive protein in U937-derived macrophages. Exp. Biol. Med. (Maywood), 2005; 230: 762-770
16. Crowell R.E., Du Clos T.W., Montoya G., Heaphy E., Mold C.: Creactive protein receptors on the human monocytic cell line U-937. Evidence for additional binding to Fc gamma RI. J. Immunol., 1991; 147: 3445-3451
17. Danenberg H.D., Szalai A.J., Swaminathan R.V., Peng L., Chen Z., Seifert P., Fay W.P., Simon D.I., Edelman E.R.: Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation, 2003; 108: 512-515
18. Devaraj S., Du Clos T.W., Jialal I.: Binding and internalization of Creactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler. Thromb. Vasc. Biol., 2005; 25: 1359-1363
19. Devaraj S., Xu D.Y., Jialal I.: C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation, 2003; 107: 398-404
20. DiCamelli R., Potempa L.A., Siegel J., Suyehira L., Petras K., Gewurz H.: Binding reactivity of C-reactive protein for polycations. J. Immunol., 1980; 125: 1933-1938
21. Diehl E.E., Haines G.K. III, Radosevich J.A., Potempa L.A.: Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. Am. J. Med. Sci., 2000; 319: 79-83
22. Dong Q., Wright J.R.: Expression of C-reactive protein by alveolar macrophages. J. Immunol., 1996; 156: 4815-4820
23. Eklund C., Jahan F., Pessi T., Lehtimaki T., Hurme M.: Interleukin 1B gene polymorphism is associated with baseline C-reactive protein levels in healthy individuals. Eur. Cytokine Netw., 2003; 14: 168-171
24. Eklund C., Lehtimaki T., Hurme M.: Epistatic effect of C-reactive protein (CRP) single nucleotide polymorphism (SNP) +1059 and interleukin-1B SNP +3954 on CRP concentration in healthy male blood donors. Int. J. Immunogenet., 2005; 32: 229-232
25. Esposito K., Pontillo A., Di Palo C., Giugliano G., Masella M., Marfella R., Giugliano D.: Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. JAMA, 2003; 289: 1799-1804
26. Ferrari S.L., Ahn-Luong L., Garnero P., Humphries S.E., Greenspan S.L.: Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J. Clin. Endocrinol. Metab., 2003; 88: 255-259
27. Fichtlscherer S., Rosenberger G., Walter D.H., Breuer S., Dimmeler S., Zeiher A.M.: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation, 2000; 102: 1000-1006
28. Fiedel B.A., Gewurz H.: Effects of C-reactive protein on platelet function. I. Inhibition of platelet aggregation and release reactions. J. Immunol., 1976; 116: 1289-1294
29. Fiedel B.A., Gewurz H.: Effects of C-reactive protein on platelet function. II. Inhibition by CRP of platelet reactivities stimulated by poly-L-lysine, ADP, epinephrine, and collagen. J. Immunol., 1976; 117: 1073-1078
30. Fiedel B.A., Gewurz H.: Cleaved forms of C-reactive protein are associated with platelet inhibition. J. Immunol., 1986; 136: 2551-2555
31. Fiedel B.A., Simpson R.M., Gewurz H.: Effects of C-reactive protein on platelet function. III. The role of cAMP, contractile elements, and prostaglandin metabolism in CRP-induced inhibition of platelet aggregation and secretion. J. Immunol., 1977; 119: 877-882
32. Fiedel B.A., Simpson R.M., Gewurz H.: Activation of platelets by modified C-reactive protein. Immunology, 1982; 45: 439-447
33. Filep J., Foldes-Filep E.: Effects of C-reactive protein on human neutrophil granulocytes challenged with N-formyl-methionyl-leucyl-phenylalanine and platelet-activating factor. Life Sci., 1989; 44: 517-524
34. Filep J.G., Herman F., Kelemen E., Foldes-Filep E.: C-reactive protein inhibits binding of platelet-activating factor to human platelets. Thromb. Res., 1991; 61: 411-421
35. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., Freed M.I.: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation, 2002; 106: 679-684
36. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R., Pepys M.B.: Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet, 1997; 349: 462-466
37. Heuertz R.M., Ahmed N., Webster R.O.: Peptides derived from Creactive protein inhibit neutrophil alveolitis. J. Immunol., 1996; 156: 3412-3417
38. Heuertz R.M., Piquette C.A., Webster R.O.: Rabbits with elevated serum C-reactive protein exhibit diminished neutrophil infiltration and vascular permeability in C5a-induced alveolitis. Am. J. Pathol., 1993; 142: 319-328
39. Heuertz R.M., Xia D., Samols D., Webster R.O.: Inhibition of C5a des Arg-induced neutrophil alveolitis in transgenic mice expressing C-reactive protein. Am. J. Physiol., 1994; 266: L649-L654
40. Kew R.R., Hyers T.M., Webster R.O.: Human C-reactive protein inhibits neutrophil chemotaxis in vitro: possible implications for the adult respiratory distress syndrome. J. Lab. Clin. Med., 1990; 115: 339-345
41. Khera A., McGuire D.K., Murphy S.A., Stanek H.G., Das S.R., Vongpatanasin W., Wians F.H.Jr., Grundy S.M., de Lemos J.A.: Race and gender differences in C-reactive protein levels. J. Am. Coll. Cardiol., 2005; 46: 464-469
42. Khreiss T., Jozsef L., Hossain S., Chan J.S., Potempa L.A., Filep J.G.: Loss of pentameric symmetry of C-reactive protein is associated with delayed apoptosis of human neutrophils. J. Biol. Chem., 2002; 277: 40775-40781
43. Khreiss T., Jozsef L., Potempa L.A., Filep J.G.: Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation, 2004; 109: 2016-2022
44. Khreiss T., Jozsef L., Potempa L.A., Filep J.G.: Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. Circulation, 2004; 110: 2713-2720
45. Kinoshita C.M., Ying S.C., Hugli T.E., Siegel J.N., Potempa L.A., Jiang H., Houghten R.A., Gewurz H.: Elucidation of a protease-sensitive site involved in the binding of calcium to C-reactive protein. Biochemistry, 1989; 28: 9840-9848
46. Koenig W., Sund M., Frohlich M., Fischer H.G., Lowel H., Doring A., Hutchinson W.L., Pepys M.B.: C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation, 1999; 99: 237-242
47. Kohayakawa M., Inoue K.: Augmentation of 1-O-alkyl-2-O-acetylsn-glycero-3-phosphocholine (PAF)-induced human platelet activation by C-reactive protein. Thromb. Res., 1986; 41: 649-657
48. Kolb-Bachofen V., Puchta-Teudt N., Egenhofer C.: Expression of membrane-associated C-reactive protein by human monocytes: indications for a selectin-like activity participating in adhesion. Glycoconj. J., 1995; 12: 122-127
49. Kovacs A., Green F., Hansson L.O., Lundman P., Samnegard A., Boquist S., Ericsson C.G., Watkins H., Hamsten A., Tornvall P.: A novel common single nucleotide polymorphism in the promoter region of the Creactive protein gene associated with the plasma concentration of Creactive protein. Atherosclerosis, 2005; 178: 193-198
50. Kresl J.J., Potempa L.A., Anderson B.E.: Conversion of native oligomeric to a modified monomeric form of human C-reactive protein. Int. J. Biochem. Cell Biol., 1998; 30: 1415-1426
51. Latkovskis G., Licis N., Kalnins U.: C-reactive protein levels and common polymorphisms of the interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease. Eur. J. Immunogenet., 2004; 31: 207-213
52. Lee R.T., Takagahara I., Lee Y.C.: Mapping the binding areas of human C-reactive protein for phosphorylcholine and polycationic compounds. Relationship between the two types of binding sites. J. Biol. Chem., 2002; 277: 225-232
53. Lindmark E., Wallentin L., Siegbahn A.: Blood cell activation, coagulation, and inflammation in men and women with coronary artery disease. Thromb. Res., 2001; 103: 249-259
54. MacGregor A.J., Gallimore J.R., Spector T.D., Pepys M.B.: Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: A comparison of monozygotic and dizygotic twins. Clin. Chem., 2004; 50: 130-134
55. Marnell L.L., Mold C., Volzer M.A., Burlingame R.W., Du Clos T.W.: C-reactive protein binds to Fc gamma RI in transfected COS cells. J. Immunol., 1995; 155: 2185-2193
56. Meier-Ewert H.K., Ridker P.M., Rifai N., Price N., Dinges D.F., Mullington J.M.: Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin. Chem., 2001; 47: 426-430
57. Miyazawa K., Kiyono S., Inoue K.: Modulation of stimulus-dependent human platelet activation by C-reactive protein modified with active oxygen species. J. Immunol., 1988; 141: 570-574
58. Mora S., Ridker P.M.: Justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention? Am. J. Cardiol., 2006; 97: 33A-41A
59. Morkowski J., Wiktorowicz K., Mackiewicz S.: Pentaksyny-struktura i funkcja. Post. Hig. Med Dosw., 1987; 41: 433-452
60. Morrow D.A., Rifai N., Antman E.M., Weiner D.L., McCabe C.H., Cannon C.P., Braunwald E.: C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy. Thrombolysis in myocardial infarction. J. Am. Coll. Cardiol., 1998; 31: 1460-1465
61. Muller H., Fehr J.: Binding of C-reactive protein to human polymorphonuclear leukocytes: evidence for association of binding sites with Fc receptors. J. Immunol., 1986; 136: 2202-2207
62. Osmand A.P., Friedenson B., Gewurz H., Painter R.H., Hofmann T., Shelton E.: Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc. Natl. Acad. Sci. USA, 1977; 74: 739-743
63. Paffen E., Vos H.L., Bertina R.M.: C-reactive protein does not directly induce tissue factor in human monocytes. Arterioscler. Thromb. Vasc. Biol., 2004; 24: 975-981
64. Pankow J.S., Folsom A.R., Cushman M., Borecki I.B., Hopkins P.N., Eckfeldt J.H., Tracy R.P.: Familial and genetic determinants of systemic markers of inflammation: The NHLBI family heart study. Atherosclerosis, 2001; 154: 681-689
65. Pasceri V., Cheng J.S., Willerson J.T., Yeh E.T.: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation, 2001; 103: 2531-2534
66. Pasceri V., Willerson J.T., Yeh E.T.: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 2000; 102: 2165-2168
67. Plenge J.K., Hernandez T.L., Weil K.M., Poirier P., Grunwald G.K., Marcovina S.M., Eckel R.H.: Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation, 2002; 106: 1447-1452
68. Potempa L.A., Maldonado B.A., Laurent P., Zemel E.S., Gewurz H.: Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium. Mol. Immunol., 1983; 20: 1165-1175
69. Potempa L.A., Siegel J.N., Fiedel B.A., Potempa R.T., Gewurz H.: Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free, human C-reactive protein subunit. Mol. Immunol., 1987; 24: 531-541
70. Potempa L.A., Zeller J.M., Fiedel B.A., Kinoshita C.M., Gewurz H.: Stimulation of human neutrophils, monocytes, and platelets by modified C-reactive protein (CRP) expressing a neoantigenic specificity. Inflammation, 1988; 12: 391-405
71. Ridker P.M.: High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation, 2001; 103: 1813-1818
72. Ridker P.M., Buring J.E., Cook N.R., Rifai N.: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation, 2003; 107: 391-397
73. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med., 1997; 336: 973-979
74. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H.: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation, 1998; 97: 425-428
75. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N.: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med., 2000; 342: 836-843
76. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., Braunwald E.: Longterm effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1999; 100: 230-235
77. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., Braunwald E.: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1998; 98: 839-844
78. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med., 2002; 347: 1557-1565
79. Ridker P.M., Stampfer M.J., Rifai N.: Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA, 2001; 285: 2481-2485
80. Rohde L.E., Hennekens C.H., Ridker P.M.: Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am. J. Cardiol., 1999; 84: 1018-1022
81. Ross R.: Atherosclerosis is an inflammatory disease. Am. Heart J., 1999; 138: S419-S420
82. Rost N.S., Wolf P.A., Kase C.S., Kelly-Hayes M., Silbershatz H., Massaro J.M., D'Agostino R.B., Franzblau C., Wilson P.W.: Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: The Framingham study. Stroke, 2001; 32: 2575-2579
83. Russell A.I., Cunninghame Graham D.S., Shepherd C., Roberton C.A., Whittaker J., Meeks J., Powell R.J., Isenberg D.A., Walport M.J., Vyse T.J.: Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum. Mol. Genet., 2004; 13: 137-147
84. Ryu S.Y., Lee Y.S., Park J., Kang M.G., Kim K.S.: Relations of plasma high-sensitivity C-reactive protein to various cardiovascular risk factors. J. Korean Med. Sci., 2005; 20: 379-383
85. Saito M., Ishimitsu T., Minami J., Ono H., Ohrui M., Matsuoka H.: Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis, 2003; 167: 73-79
86. Salonen E.M., Vartio T., Hedman K., Vaheri A.: Binding of fibronectin by the acute phase reactant C-reactive protein. J. Biol. Chem., 1984; 259: 1496-1501
87. Schwedler S.B., Amann K., Wernicke K., Krebs A., Nauck M., Wanner C., Potempa L.A., Galle J.: Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation, 2005; 112: 1016-1023
88. Shephard E.G., Anderson R., Rosen O., Myer M.S., Fridkin M., Strachan A.F., De Beer F.C.: Peptides generated from C-reactive protein by a neutrophil membrane protease. Amino acid sequence and effects of peptides on neutrophil oxidative metabolism and chemotaxis. J. Immunol., 1990; 145: 1469-1476
89. Shephard E.G., Beer S.M., Anderson R., Strachan A.F., Nel A.E., De Beer F.C.: Generation of biologically active C-reactive protein peptides by a neutral protease on the membrane of phorbol myristate acetate-stimulated neutrophils. J. Immunol., 1989; 143: 2974-2981
90. Singh U., Devaraj S., Jialal I.: C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler. Thromb. Vasc. Biol., 2005; 25: 2216-2221
91. Sothern R.B., Roitman-Johnson B., Kanabrocki E.L., Yager J.G., Roodell M.M., Weatherbee J.A., Young M.R., Nenchausky B.M., Scheving L.E.: Circadian characteristics of circulating interleukin-6 in men. J. Allergy Clin. Immunol., 1995; 95: 1029-1035
92. Suk H.J., Ridker P.M., Cook N.R., Zee R.Y.: Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis, 2005; 178: 139-145
93. Swanson S.J., McPeek M.M., Mortensen R.F.: Characteristics of the binding of human C-reactive protein (CRP) to laminin. J. Cell Biochem., 1989; 40: 121-132
94. Szalai A.J., McCrory M.A., Cooper G.S., Wu J., Kimberly R.P.: Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun., 2002; 3: 14-19
95. Taskinen S., Hyvonen M., Kovanen P.T., Meri S., Pentikainen M.O.: C-reactive protein binds to the 3beta-OH group of cholesterol in LDL particles. Biochem. Biophys. Res. Commun., 2005; 329: 1208-1216
96. Taskinen S., Kovanen P.T., Jarva H., Meri S., Pentikainen M.O.: Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. Biochem. J., 2002; 367: 403-412
97. Tchernof A., Nolan A., Sites C.K., Ades P.A., Poehlman E.T.: Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation, 2002; 105: 564-569
98. Tillett W.S., Francis T. Jr: Serological reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. J. Exp. Med., 1930; 52: 561-585
99. Tohgi H., Konno S., Takahashi S., Koizumi D., Kondo R., Takahashi H.: Activated coagulation/fibrinolysis system and platelet function in acute thrombotic stroke patients with increased C-reactive protein levels. Thromb. Res., 2000; 100: 373-379
100. Torzewski J., Torzewski M., Bowyer D.E., Frohlich M., Koenig W., Waltenberger J., Fitzsimmons C., Hombach V.: C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler. Thromb. Vasc. Biol., 1998; 18: 1386-1392
101. Torzewski M., Rist C., Mortensen R.F., Zwaka T.P., Bienek M., Waltenberger J., Koenig W., Schmitz G., Hombach V., Torzewski J.: C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol., 2000; 20: 2094-2099
102. Tseng J., Mortensen R.F.: Binding of human C-reactive protein (CRP) to plasma fibronectin occurs via the phosphorylcholine-binding site. Mol. Immunol., 1988; 25: 679-686
103. Venugopal S.K., Devaraj S., Jialal I.: C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation, 2003; 108: 1676-1678
104. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., Jialal I.: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation, 2002; 106: 1439-1441
105. Verma S., Li S.H., Badiwala M.V., Weisel R.D., Fedak P.W., Li R.K., Dhillon B., Mickle D.A.: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation, 2002; 105: 1890-1896
106. Verma S., Szmitko P.E., Yeh E.T.: C-reactive protein: structure affects function. Circulation, 2004; 109: 1914-1917
107. Verma S., Wang C.H., Li S.H., Dumont A.S., Fedak P.W., Badiwala M.V., Dhillon B., Weisel R.D., Li R.K., Mickle D.A., Stewart D.J.: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation, 2002; 106: 913-919
108. Vickers M.A., Green F.R., Terry C., Mayosi B.M., Julier C., Lathrop M., Ratcliffe P.J., Watkins H.C., Keavney B.: Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc. Res., 2002; 53: 1029-1034
109. Vigo C.: Effect of C-reactive protein on platelet-activating factor-induced platelet aggregation and membrane stabilization. J. Biol. Chem., 1985; 260: 3418-3422
110. Vigushin D.M., Pepys M.B., Hawkins P.N.: Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J. Clin. Invest., 1993; 91: 1351-1357
111. Vlaicu R., Rus H.G., Niculescu F., Cristea A.: Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis, 1985; 55: 35-50
112. Volanakis J.E.: Human C-reactive protein: expression, structure, and function. Mol. Immunol., 2001; 38: 189-197
113. Wang H.W., Sui S.F.: Dissociation and subunit rearrangement of membrane-bound human C-reactive proteins. Biochem. Biophys. Res. Commun., 2001; 288: 75-79
114. Wang H.W., Wu Y., Chen Y., Sui S.F.: Polymorphism of structural forms of C-reactive protein. Int. J. Mol. Med., 2002; 9: 665-671
115. Wolford J.K., Gruber J.D., Ossowski V.M., Vozarova B., Antonio Tataranni P., Bogardus C., Hanson R.L.: A C-reactive protein promoter polymorphism is associated with type 2 diabetes mellitus in Pima Indians. Mol. Genet. Metab., 2003; 78: 136-144
116. Yeh E.T., Willerson J.T.: Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation, 2003; 107: 370-371
117. Zee R.Y., Ridker P.M.: Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis, 2002; 162: 217-219
118. Zouki C., Beauchamp M., Baron C., Filep J.G.: Prevention of In vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J. Clin. Invest., 1997; 100: 522-529
119. Zouki C., Haas B., Chan J.S., Potempa L.A., Filep J.G.: Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion. J. Immunol., 2001; 167: 5355-5361
120. Zwaka T.P., Hombach V., Torzewski J.: C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation, 2001; 103: 1194-1197